Quantcast

Latest immunotherapy Stories

2014-07-24 08:33:56

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients...

2014-07-23 08:32:38

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment...

2014-07-17 08:25:12

MONMOUTH JUNCTION, N.J., July 17, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany....

2014-07-16 08:27:11

OXFORD, England and INDIANAPOLIS, July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body's own immune system to attack cancer cells. ImmTACs...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-14 16:24:17

- TNIB extends record date pursuant to a demand by shareholders. ORLANDO, Fla., July 14, 2014 /PRNewswire/ -- TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company"), a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB. The Company's Board received a Letter on July 13, 2014 from Carricklee Consulting Ltd on behalf of...

2014-07-14 08:26:52

Company Commemorates its Transformative Acquisition of EGEN, Inc. and the Initiation of the Phase III Pivotal OPTIMA Study in Primary Liver Cancer LAWRENCEVILLE, N.J., July 14, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY. President and CEO Michael H. Tardugno and members of the Celsion and...

2014-07-10 23:10:54

Tampa Bay Research Institute (TBRI), a well-respected private, non-profit biomedical research institute, announced today that its most recent findings describing how the pine cone extract affects the immune system have been published in the journal, BMC Complementary and Alternative Medicine. (PRWEB) July 10, 2014 Tampa Bay Research Institute (TBRI), a well-respected private, non-profit biomedical research institute, announced today that TBRI's most recent findings describing how the...

2014-07-10 20:22:35

VIENNA, Va., July 10, 2014 /PRNewswire-USNewswire/ -- Allergy & Asthma Network, a leading nonprofit patient education organization, invites you to join its "2014 Venom Allergy 101" webinar on July 24, 2014, at 7 p.m. EST. This webinar is perfect for the summer as stinging insects abound in outdoor areas. Learn how to protect yourself from stings as well as how to respond and treat a potential allergic reaction. Venom allergies are caused by five types of insects: honey bees,...

2014-07-10 08:27:19

SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today a publication that reviews data from the company's oncolytic immunotherapy program, including its lead product Pexa-Vec. Additionally, the publication outlines the rationale for combination therapy with other cancer immunotherapies, such as...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related